A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma
Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
Within the next decade, pancreatic ductal adenocarcinoma (PDAC) is expected to rise to the
second leading cause of cancer-related mortality. To increase the survival, various
peri-operative treatments have been tested, and adjuvant FOLFIRINOX or gemcitabine plus
capecitabine is now standard of care after surgical resection for localized PDAC. Even with
superior survival among various disease extent of PDAC, resectable PDAC still shows poor
outcomes with surgery followed by adjuvant chemotherapy. This phase II study is investigating
the role of modified-FOLFIRINOX as neoadjuvant treatment for resectable PDAC.